Edward Yung, MD
Ophthalmology · Upland, CANPI 1225391725
Payments from drug & device makers
Across 569 payments — averaging $289.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$40K
- AbbVie$29K
- NEW World Medical,inc.$26K
- Glaukos Corporation$22K
- Aerie Pharmaceuticals, Inc.$17K
- Alcon Research LLC$11K
- plus $20K from 19 others
Across 3 payments — averaging $6203.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$19K
What the payments were for
- Consulting fees$59,86436%
- Speaking & faculty fees$80,31949%
- Travel & lodging$1290%
- Food & beverage$24,39815%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 104 | $39,898 |
| AbbVie(2 entities) | 143 | $29,376 |
| NEW World Medical,inc. | 83 | $25,952 |
| Glaukos Corporation | 44 | $22,216 |
| Aerie Pharmaceuticals, Inc. | 33 | $17,084 |
| Alcon Research LLC | 6 | $10,695 |
| Nova Eye, Inc. | 7 | $6,493 |
| Ivantis, Inc | 18 | $4,759 |
| Bausch & Lomb Americas Inc. | 36 | $3,226 |
| Tarsus Pharmaceuticals, Inc. | 30 | $2,177 |
| Sight Sciences, Inc. | 14 | $753 |
| Oyster Point Pharma, Inc. | 22 | $689 |
| Oculus Surgical Inc. | 1 | $500 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $245 |
| Dompe US, Inc. | 5 | $181 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $128 |
| Novartis | 5 | $83 |
| Thea Pharma Inc. | 3 | $64 |
| Ocular Therapeutix, Inc. | 2 | $62 |
| Beaver-visitec International, Inc. | 1 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Harrow Eye, LLC | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$52,180
- Rhopressa$47,271
- DURYSTA$16,529
- Ahmed Glaucoma Valve$13,397
- Kahook Dual Blade$13,397
- SIMBRINZA$12,750
- Clearpath$11,747
- Streamline$11,747
- iDose$10,191
- Via360$7,691
- Hydrus Microstent$3,029
- Travoprost Intraocular Implant - iDose$2,625
- iDose Trio$2,250
- Hydrus$1,900
- iAccess Precision Blade$1,350
- XDEMVY$1,200
- OZURDEX$1,200
- iDose TR$831
- Streamline Surgical System$630
- GONIO ready$500
How this compares
$164,811 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 267 | $138,459 |
| XdemvyLotilaner | 75 | $137,604 |
| RhopressaNetarsudil Mesylate | 333 | $129,398 |
| RestasisCyclosporine | 67 | $84,777 |
| RocklatanNetarsudil Mesylat/Latanoprost | 134 | $52,241 |
| XiidraLifitegrast | 20 | $33,699 |
| VyzultaLatanoprostene Bunod | 69 | $31,716 |
| Brimonidine Tartrate | 756 | $29,297 |
| CombiganBrimonidine Tartrate/Timolol | 53 | $22,703 |
| Prednisolone Acetate | 477 | $21,146 |
| Alphagan PBrimonidine Tartrate | 57 | $20,355 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 123 | $18,587 |
| TyrvayaVarenicline Tartrate | 31 | $17,879 |
| Cyclosporine | 41 | $16,455 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 60 | $15,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $29,376 | $266,294444 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $17,084 | $181,639467 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,177 | $137,60475 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $3,226 | $77,689101 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $689 | $17,87931 claims |
| AlconSimbrinza | $39,898 | $15,86460 claims |
| NovartisIlevro | $83 | $13,87538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Upland
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.